|Bid||0.00 x 1000|
|Ask||208.27 x 1000|
|Day's Range||201.63 - 206.46|
|52 Week Range||117.06 - 218.00|
|Beta (5Y Monthly)||0.28|
|PE Ratio (TTM)||30.12|
|Earnings Date||Apr 27, 2021|
|Forward Dividend & Yield||3.40 (1.66%)|
|Ex-Dividend Date||Feb 11, 2021|
|1y Target Est||216.14|
At the same time, Moody's revised Alvogen's outlook to negative from stable.The negative outlook reflects the risk that Alvogen will be unable to delever to 5x debt/EBITDA in 2021, at a time when it also faces rising refinancing risk. Alvogen's financial leverage declined materially in 2020 but still remains very high, owing in part to product shipment delays with a key government contract.
Eli Lilly and Company (NYSE: LLY) will participate in the Cowen and Company 41st Annual Health Care Conference on Thursday, March 4, 2021. Daniel Skovronsky, M.D., Ph.D., Lilly's Chief Scientific Officer and President of Lilly Research Laboratories, will participate in a fireside chat at 9:10 a.m., Eastern Time.
In this article we are going to list the top 15 pharmaceutical companies with the highest R&D spending. Click to skip ahead and jump to the Top 5 Pharmaceutical Companies With Highest R&D Spending. Pharma companies have always been among the most important companies in the world, even if they have been much maligned as […]